Mr. Li Yuhui has been the “Forbes China Top 100 Venture Capitalists” for the last 7 consecutive years. He has over 25 years of experience in China’s VC industry, with a long track record on investing in sci-tech innovation. He founded Panlin Capital in 2010 and established Panlin's investment strategy, which focuses on early to mid-stage healthcare and to B& tech investments, and achieved an outstanding performance.

Mr. Li is in charge of investing in early stage healthcare companies such as Kangtai Bio (300601), Hybribio (300639), Ribo Life Science, Virogin, and Endocell.  Mr. Li also invests in early stage enterprise-service providers such as Passiontec (fully acquired by Meituan), Ruiyun Cold Chain ，Easy-Logic Technology and PPIO. He  has invested in growth stage companies such as Toread (300005), Eastern Pioneer (603377), BGE (603588), Sun Shine (acquired by Hong Kong Royal Group (002329)) and XGimi Technology (688696).

Before founding Panlin Capital, Mr. Li had worked over 10 years in top-tier Chinese investment banks, such as Junan Securities and Guotai Junan Securities, where he accumulated experience in investment banking and team management. Prior to his investment banking career, he worked as a CAD developer in a large SOE for three years.

Mr. Li holds a bachelor’s degree of mechanical engineering from Huazhong University of Science and Technology, a master’s degree of Economics (Finance Major) from Southwestern University of Finance and Economics, and an EMBA degree from Tsinghua University.